<DOC>
	<DOCNO>NCT01899326</DOCNO>
	<brief_summary>This pilot clinical trial study well desipramine hydrochloride filgrastim work stem cell mobilization patient multiple myeloma undergoing stem cell transplant . Giving colony-stimulating factor , filgrastim , drug , desipramine hydrochloride , help stem cell move patient 's bone marrow blood collect store .</brief_summary>
	<brief_title>Desipramine Hydrochloride Filgrastim For Stem Cell Mobilization Patients With Multiple Myeloma Undergoing Stem Cell Transplant</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To study efficacy , safety , harvest kinetics engraftment kinetics patient undergo autologous stem cell mobilization , mobilize combination granulocyte colony-stimulating factor ( GCSF ) ( filgrastim ) desipramine ( desipramine hydrochloride ) ( G+D ) . II . To analyze polymorphisms adrenergic receptor beta 2 ( ADRB2 ) adrenergic receptor beta 3 ( ADRB3 ) gene correlate mobilization efficiency . OUTLINE : Patients receive desipramine hydrochloride orally ( PO ) daily day -3 +4 filgrastim PO twice daily ( BID ) day 1-4 . Stem cell collection begin day 6 . After completion study treatment , patient follow 1 week completion stem cell collection .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Desipramine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Patients eligible autologous stem cell transplant multiple myeloma ; plan use filgrastim ( GCSF ) stem cell mobilization Ability give inform consent Glomerular filtration rate ( GFR ) &gt; 30 ml/minute Liver function test &lt; 2.5 x upper limit normal ( ULN ) Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 2 less Based prior therapy patient classify two category : Initial mobilizers exposure alkylators Remobilizers prior exposure alkylators great 5 cycle lenalidomide therapy prior mobilization Use monoamine oxidase inhibitor ( MAOI ) within 2 week desipramine therapy Concomitant therapy drug show major interaction desipramine Concurrent use drug contraindicate desipramine Myocardial infarction precede 4 week ; history uncontrolled cardiac arrhythmia family history sudden cardiac death ; baseline correct QT ( QTc ) &gt; 460 msec Active alcohol abuse Bipolar disorder Untreated active major depression History seizures past 3 year Pregnancy lactation ; refusal use adequate contraception Uncontrolled thyroid disease GCSF pegfilgrastim use within 14 day prior enrollment Bortezomib , Revlimid thalidomide use within 7 day enrollment Patients sickle cell disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>